Transcode Therapeutics (RNAZ) Total Non-Current Liabilities (2020 - 2026)

Transcode Therapeutics (RNAZ) has reported Total Non-Current Liabilities for 6 consecutive years, with $7.3 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Total Non-Current Liabilities rose 1209.92% year-over-year to $7.3 million; the trailing twelve-month figure through Jun 2026 stood at $7.3 million (up 1209.92% YoY), and the FY2025 full-year result was $7.0 million, up 7.38% from the prior year.
• Total Non-Current Liabilities held at $7.3 million in Q2 2026 per RNAZ's latest filing, from $7.3 million in the prior quarter.
• Across five years, Total Non-Current Liabilities topped out at $7.3 million in Q1 2026 and bottomed at $38291.0 in Q4 2023.
• Historically, Total Non-Current Liabilities has averaged $3.7 million across 4 years, with a median of $3.7 million in 2024.
• The sharpest annual moves came in 2024 and 2025: Total Non-Current Liabilities soared 16983.38% in 2024, then rose 7.38% in 2025.
• Over 4 years, Total Non-Current Liabilities stood at $38291.0 in 2023, then jumped by 16983.38% to $6.5 million in 2024, then gained by 7.38% to $7.0 million in 2025, then gained by 3.26% to $7.3 million in 2026.
• According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $7.3 million, $7.3 million, and $7.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.